Neoadjuvant and Adjuvant Treatment in Early-Stage NSCLC: Options Are Expanding – An In the Clinic Activity Evaluation (ID: i841-1) Question Title * 1. How many years have you been in practice? ≥21 11-20 1-10 <1 Question Title * 2. How many patients with NSCLC do you manage per week? 1 to 10 11 to 25 26 to 50 I am not directly involved in patient care Question Title * 3. Please select the option that best describes your practice setting: Academic medical center Community-based cancer center Research Question Title * 4. After participating in this activity, how confident are you now in the management of patients with NSCLC in your practice? Very confident Confident Neutral Little confidence No confidence Question Title * 5. How committed are you to making changes in your practice based on your participation in this activity? Very committed Committed Neutral Not committed I do not plan to make changes If not committed or do not plan to make changes, please indicate reason Question Title * 6. Which of the following best describes the impact of this activity on your performance? I gained new strategies/skills/information I can apply to my area of practice I need more information before I can change my practice My practice is already consistent with the information presented This activity will not change my practice Question Title * 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply. Increased familiarity with biomarkers commonly found in NSCLC Increased familiarity with treatment selection in regards to PD-1/PD-L1 inhibitors for treatment in the neoadjuvant or adjuvant setting for early-stage NSCLC Identify appropriate biomarker testing that is necessary for certain I/O therapies Tailor treatment options based on biomarker results Consider using a PD-1/PD-L1 inhibitor for early-stage NSCLC in the adjuvant or neoadjuvant setting Tailor therapies based on best practices Review of trials emerging for treatment with immunotherapies in early-stage NSCLC Gained knowledge of potential new treatments for immunotherapies in early-stage NSCLC Other (please specify) Question Title * 8. What barriers do you see to making changes in your practice? Please select all that apply. Lack of knowledge regarding evidence-based strategies Lack of convincing evidence to warrant change Lack of time/resources to consider change Insurance, reimbursement, or legal issues Conflicting guidelines or evidence Patient compliance and/or patient resource barriers Other (please specify) Question Title * 9. Please rate your level of agreement by checking the appropriate rating.After participating in today’s activity, I am now better able to: Strongly agree Agree Neutral Disagree Strongly disagree Select optimal treatment for patients with early-stage NSCLC based on appropriate staging and patient-/treatment-related factors Select optimal treatment for patients with early-stage NSCLC based on appropriate staging and patient-/treatment-related factors Strongly agree Select optimal treatment for patients with early-stage NSCLC based on appropriate staging and patient-/treatment-related factors Agree Select optimal treatment for patients with early-stage NSCLC based on appropriate staging and patient-/treatment-related factors Neutral Select optimal treatment for patients with early-stage NSCLC based on appropriate staging and patient-/treatment-related factors Disagree Select optimal treatment for patients with early-stage NSCLC based on appropriate staging and patient-/treatment-related factors Strongly disagree Integrate testing strategies into the treatment planning process for patients with early-stage disease Integrate testing strategies into the treatment planning process for patients with early-stage disease Strongly agree Integrate testing strategies into the treatment planning process for patients with early-stage disease Agree Integrate testing strategies into the treatment planning process for patients with early-stage disease Neutral Integrate testing strategies into the treatment planning process for patients with early-stage disease Disagree Integrate testing strategies into the treatment planning process for patients with early-stage disease Strongly disagree Assess evolving data on the use of adjuvant and neoadjuvant immunotherapy for the management of patients with early-stage NSCLC and strategies for optimizing immunotherapy in routine clinical practice Assess evolving data on the use of adjuvant and neoadjuvant immunotherapy for the management of patients with early-stage NSCLC and strategies for optimizing immunotherapy in routine clinical practice Strongly agree Assess evolving data on the use of adjuvant and neoadjuvant immunotherapy for the management of patients with early-stage NSCLC and strategies for optimizing immunotherapy in routine clinical practice Agree Assess evolving data on the use of adjuvant and neoadjuvant immunotherapy for the management of patients with early-stage NSCLC and strategies for optimizing immunotherapy in routine clinical practice Neutral Assess evolving data on the use of adjuvant and neoadjuvant immunotherapy for the management of patients with early-stage NSCLC and strategies for optimizing immunotherapy in routine clinical practice Disagree Assess evolving data on the use of adjuvant and neoadjuvant immunotherapy for the management of patients with early-stage NSCLC and strategies for optimizing immunotherapy in routine clinical practice Strongly disagree Question Title * 10. Please rate your level of agreement by checking the appropriate rating.Justin F. Gainor, MD effectively: Strongly agree Agree Neutral Disagree Strongly disagree Presented the material Presented the material Strongly agree Presented the material Agree Presented the material Neutral Presented the material Disagree Presented the material Strongly disagree Avoided commercial bias or influence Avoided commercial bias or influence Strongly agree Avoided commercial bias or influence Agree Avoided commercial bias or influence Neutral Avoided commercial bias or influence Disagree Avoided commercial bias or influence Strongly disagree Question Title * 11. Please rate your level of agreement by checking the appropriate rating.Jacob M. Sands, MD effectively: Strongly agree Agree Neutral Disagree Strongly disagree Presented the material Presented the material Strongly agree Presented the material Agree Presented the material Neutral Presented the material Disagree Presented the material Strongly disagree Avoided commercial bias or influence Avoided commercial bias or influence Strongly agree Avoided commercial bias or influence Agree Avoided commercial bias or influence Neutral Avoided commercial bias or influence Disagree Avoided commercial bias or influence Strongly disagree Question Title * 12. Please rate your level of agreement by checking the appropriate rating.The content presented: Strongly agree Agree Neutral Disagree Strongly disagree Enhanced my current knowledge base Enhanced my current knowledge base Strongly agree Enhanced my current knowledge base Agree Enhanced my current knowledge base Neutral Enhanced my current knowledge base Disagree Enhanced my current knowledge base Strongly disagree Addressed my most pressing questions Addressed my most pressing questions Strongly agree Addressed my most pressing questions Agree Addressed my most pressing questions Neutral Addressed my most pressing questions Disagree Addressed my most pressing questions Strongly disagree Promoted improvements or quality in health care Promoted improvements or quality in health care Strongly agree Promoted improvements or quality in health care Agree Promoted improvements or quality in health care Neutral Promoted improvements or quality in health care Disagree Promoted improvements or quality in health care Strongly disagree Was scientifically rigorous and evidence based Was scientifically rigorous and evidence based Strongly agree Was scientifically rigorous and evidence based Agree Was scientifically rigorous and evidence based Neutral Was scientifically rigorous and evidence based Disagree Was scientifically rigorous and evidence based Strongly disagree Was free of commercial bias Was free of commercial bias Strongly agree Was free of commercial bias Agree Was free of commercial bias Neutral Was free of commercial bias Disagree Was free of commercial bias Strongly disagree Question Title * 13. If you indicated that you perceived commercial bias or influence, please describe: Question Title * 14. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice? Question Title * 15. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for lung cancer/NSCLC: Done
